AZ's lesinurad misses in Phase III gout at lower dose
This article was originally published in Scrip
Executive Summary
AstraZeneca's gout treatment lesinurad used in combination with Takeda Pharmaceutical's Uloric (febuxostat), has missed its primary endpoint at the lower 200mg dose tested in another Phase III trial.
You may also be interested in...
Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.